Abpro Holdings Announces Submission of an Ind Application to Initiate a Phase 1 Clinical Trial of T Cell Engager Abp-102/Ct-P72 for Her2-Positive Cancers

THOMSON REUTERS
Dec 15, 2025

Abpro Holdings Announces Submission of an Ind Application to Initiate a Phase 1 Clinical Trial of T Cell Engager Abp-102/Ct-P72 for Her2-Positive Cancers

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10